Sinorda Pharmaceutical presented four posters at APDW for discussion.

The 2023 Asia-Pacific Digestive Disease Week (APDW 2023) was held from December 6 to 9 at the Queen Sirikit National Convention Center in Thailand. This year’s conference marked APDW’s 20th anniversary and also represented the first meeting held after the pandemic.

Professor Hu Pingsheng, Chairman of Sinorda Pharma, represented the company at this year's conference and presented clinical study data spanning from Phase I to Phase III for the company's novel drug, X842 Liposome Capsules. This marks Sinorda Pharma's first participation in an international professional academic conference since the pandemic, drawing significant attention from gastrointestinal experts across numerous Southeast Asian countries—including the conference chair—and sparking anticipation for potential clinical research collaborations with Sinorda Pharma.

About X842

X842 is a next-generation, orally administered potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by competitively blocking the potassium-ion activity within the H-K-ATPase enzyme. Compared to traditional proton pump inhibitors (PPIs), P-CAB drugs offer several advantages: rapid onset of action (achieving full efficacy after just one dose), prolonged acid suppression (particularly effective in maintaining nighttime acid control), convenient dosing (no need to take before meals), and fewer adverse reactions.

X842's first indication is gastroesophageal reflux disease (GERD), and clinical Phase I-III trials have now been completed, paving the way for the New Drug Application (NDA) submission process. The product is expected to launch in China during the first quarter of 2024.

Market Outlook

The incidence of acid-related diseases continues to rise year by year. Currently, the therapeutic drugs available on the market come with certain side effects and pose challenges related to drug resistance. As a novel P-CAB medication, X842 boasts a unique mechanism of action and remarkable therapeutic efficacy, offering patients a brand-new treatment option.

Sinorda Pharmaceutical plans to further advance project licensing in Southeast Asia, paving the way for the widespread global adoption of X842. We look forward to the drug's early market launch, bringing greater benefits to patients worldwide.